# Cancer Biology Program (01)

> **NIH NIH P30** · RESEARCH INST OF FOX CHASE CAN CTR · 2020 · $8,695

## Abstract

PROJECT SUMMARY/ABSTRACT – CANCER BIOLOGY PROGRAM
The Cancer Biology (CB) Program, led by Chernoff and Testa is comprised of 19 Primary Members and 11
Collaborating Members. Program funding is $4.2M (project direct costs) annually, including $3.5M in peer-
reviewed funding of which $1.9M is from the NCI. CB members have been highly productive and interactive
during the past funding cycle, generating 534 publications, with 26% representing intra-programmatic and 33%
representing inter-programmatic collaborations.
The primary mission of the Cancer Biology (CB) Program is to determine how a normal cell becomes
transformed and develops into a cancer. The Program now includes a range of studies that use cell-based and
animal models, as well as patient-derived materials, to analyze and exploit altered signal transduction
pathways in cancer cells, to explore interactions between tumor cells and their microenvironment, and to
identify therapeutically useful properties of normal and transformed stem cells. These changes in scientific
scope have been accompanied both by expansion in membership and inter- and intra-programmatic
collaborations.
The scientific platform of the CB Program is built on three pillars: altered cancer cell signaling, cancer stem cell
biology, and the contributions of the stroma to cancer, with an overarching interest in how abnormalities in
these domains promote the initiation and maintenance of cell transformation, invasion, and metastasis. The CB
Program occupies a vital niche at Fox Chase Cancer Center (FCCC), allied to, but distinct from, the Molecular
Therapeutics (MT) Program, and represents the core of molecular oncology research at this Institution. In
addition, as the major home for signal transduction research at FCCC, the investigators in the CB Program are
heavily involved in translational efforts to find useful new drug targets that regulate key neoplastic signaling
pathways. Future plans center on strengthening, by means of strategic recruiting, the links between
investigators studying aberrant signaling pathways in cancer cells (including cancer stem cells), and in the
surrounding stroma, with the ultimate goal of translating these insights, in coordination with the MT Program,
into clinical practice. All these activities are enabled by and heavily reliant upon Shared Resources as indicated
by program usage of all 12 CCSG-supported Shared Resources.

## Key facts

- **NIH application ID:** 10113017
- **Project number:** 3P30CA006927-54S4
- **Recipient organization:** RESEARCH INST OF FOX CHASE CAN CTR
- **Principal Investigator:** JONATHAN CHERNOFF
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $8,695
- **Award type:** 3
- **Project period:** — → —

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10113017

## Citation

> US National Institutes of Health, RePORTER application 10113017, Cancer Biology Program (01) (3P30CA006927-54S4). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10113017. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*